Krall et al. showed that KEAP1 loss is involved in the resistance of NSCLC cell lines with mutations in EGFR, ALK, B-RAF and K/N-RAS to selective inhibitors of these kinases [127]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.